Analyst Activity – FBR & Co Reiterates Outperform on AVEO Pharmaceuticals (NASDAQ:AVEO)

105

Analyst Ratings For AVEO Pharmaceuticals (NASDAQ:AVEO)

Story continues below

Today, FBR & Co reiterated its Outperform rating on AVEO Pharmaceuticals (NASDAQ:AVEO) with a price target of $3.00.

There are 2 buy ratings on the stock.

The current consensus rating on AVEO Pharmaceuticals (NASDAQ:AVEO) is Buy (Score: 3.00) with a consensus target price of $2.35 per share, a potential 199.17% upside.

Some recent analyst ratings include

  • 2/27/2017-FBR & Co Reiterated Rating of Outperform.
  • 6/16/2016-Piper Jaffray Companies Reiterated Rating of Buy.
  • 3/9/2015-Royal Bank of Canada Upgrade from a “Underperform ” rating to a ” Sector Perform” rating.

Dividend information for AVEO Pharmaceuticals (NASDAQ:AVEO)

.
Recent Insider Trading Activity For AVEO Pharmaceuticals (NASDAQ:AVEO)
AVEO Pharmaceuticals (NASDAQ:AVEO) has insider ownership of 5.10% and institutional ownership of 37.94%.

  • On 1/16/2015 Matthew D Dallas, VP Sell, 3,075 $0.82 with an average share price of $2,521.50 View SEC Filing   1/7/2015 per share and the total transaction amounting to Michael P Bailey.
  • On 1/30/2014 Joseph Vittiglio, SVP Sell, 5,430 $1.64 with an average share price of $8,905.20 View SEC Filing   3/14/2013 per share and the total transaction amounting to David Brannon Johnston.
  • On 3/7/2013 Henri A Termeer, Director Buy, 55,499 $6.73 with an average share price of $373,508.27 View SEC Filing   12/13/2012 per share and the total transaction amounting to Ngoc Tuan Ha.
  • On 12/13/2012 Robert C Young, Director Buy, 2,371 $6.78 with an average share price of $16,075.38 View SEC Filing   12/3/2012 per share and the total transaction amounting to Robert C Young.
  • On 9/13/2012 David Brannon Johnston, CFO Sell, 1,386 $10.60 with an average share price of $14,691.60 View SEC Filing   8/8/2012 per share and the total transaction amounting to Robert C Young.

About AVEO Pharmaceuticals (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Recent Trading Activity for AVEO Pharmaceuticals (NASDAQ:AVEO)
Shares of AVEO Pharmaceuticals closed the previous trading session at 0.785 0.000 0.00% with 299,676 shares trading hands.

An ad to help with our costs